Ovid Therapeutics INC Form 4 insider transactions

Ovid Therapeutics director Karen Bernstein was granted 90,000 stock options on December 12, 2024, which vest over 36 months.

Margaret A. Alexander, President and COO of Ovid Therapeutics, reports the acquisition of 140,000 employee stock options.

Ovid Therapeutics' Chief Business and Financial Officer, Jeffrey Rona, was granted options to purchase 315,000 shares of common stock.

Ovid Therapeutics CEO Jeremy Levin purchased 18,248 shares of common stock at an average price of $2.76.